Research programme: Alzheimer's disease therapeutics - BTG/Senexis

Drug Profile

Research programme: Alzheimer's disease therapeutics - BTG/Senexis

Alternative Names: Amyloid-beta oligomerisation inhibitors; Aβ oligomerisation inhibitors; BGC 200406; BGC 200466; BGC 201178; RS 0406; RS 0466; RS 1178; SEN-1269

Latest Information Update: 21 Aug 2009

Price : $50

At a glance

  • Originator BTG
  • Developer Senexis
  • Class Peptides; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 29 Jan 2008 Preclinical development is ongoing
  • 03 Mar 2006 This programme has been licensed to Senexis
  • 06 Nov 2003 Preclinical trials in Alzheimer's disease in United Kingdom (Intracerebro-ventricular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top